PEDIATRIC PHARMACOKINETIC: INFLUENCE AND IMPORTANCE

Main Article Content

C. K. SAHOO
B. RAY
AMIYAKANTA MISHRA
BIBHANWITA SATPATHY
CHINMAYA RATH

Abstract

Pharmacokinetic is the movement pattern of drug throughout the body. The study of Pharmacokinetic parameter is immense important during therapy which focus the accurate concentration of drug in plasma and its clearance. The study also suggests the appropriate doses and route of administration for rapid and successful action of Drug. In case of lower age group like pediatric community, the detail study of pharmacokinetic many times enables the safe use of drug as in case of Pediatric group many system like enzyme and excretion criteria are remaining in Underdeveloped condition. Population based models can also limit the sampling required from each individual by increasing the overall sample size to generate robust pharmacokinetic data. This review details key considerations in the design and development of pediatric Pharmacokinetic Parameter.

Keywords:
Pharmacokinetics, ADME, pediatric drug development, physiology, Absorption, Distribution

Article Details

How to Cite
SAHOO, C. K., RAY, B., MISHRA, A., SATPATHY, B., & RATH, C. (2021). PEDIATRIC PHARMACOKINETIC: INFLUENCE AND IMPORTANCE. Asian Journal of Advances in Medical Science, 3(4), 195-204. Retrieved from http://mbimph.com/index.php/AJOAIMS/article/view/2537
Section
Review Article

References

Aslan YY, Koca LL, Mutlu MM, et al. Apopitotic effects of dopamine and dobutamine on neutrophils of premature neonates. J Matern Fetal Neonatal Med. 2011;24:1155–1158. DOI:10.3109/14767058.2010.545914

Banner W, Vernon DD, Minton SD, Dean JM. Nonlinear dobutamine pharmacokinetics in a pediatric population. Crit Care Med. 1991;19:871–873.

Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. BMJ. 2000;320:79–82.

Coté CJ, Kauffman RE, Troendle GJ, Lambert GH (1996) Is the “therapeutic orphan” about to be adopted? Pediatrics 98:118–123

Driscoll DJ. Use of inotropic and chronotropic agents in neonates. Clin Perinatol. 1987;14: 931–949.

EMA. Revised priority list for studies into off-patent paediatric medical products. European Medicines Agency, London, EMA/480197/ 2010. 2020;1–8.

Filippi L, Pezzati M, Poggi C, et al. Dopamine versus dobutamine in very low birthweight infants: endocrine effects. Arch Dis Child Fetal Neonatal Ed. 2077;92:F367–F371. DOI:10.1136/adc.2006.098566

Greenough A, Emery EF. Randomized trial comparing dopamine and dobutamine in preterm infants. Eur J Pediatr. 1993;152:925–927

Hamamichi Y, Ichida F, Tsubata S, et al. Dobutamine stress radionuclide ventricul- ography reveals silent myocardial dysfunction in Kawasaki disease. Circ J. 2002;66:63–69.

Jose AB, Niguidula DF, Botros S, et al. Hemodynamic effects of dobutamine in children; 1981.

Kates RE, Leier CV. Dobutamine pharmaco- kinetics in severe heart failure. Clin Pharmacol Ther. 1978;24:537–541.

Lorenz JM, Kleinman LI, Ahmed G, Markarian K. Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics. 1995;96:484–489.

Lorenz JM, Kleinman LI, Ahmed G, Markarian K. Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics. 1995;96:484–489.

Osborn D, Evans N, Kluckow M. Randomized trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr. 2002;140:183–191

Perkin RM, Levin DL, Webb R, et al. Dobutamine: a hemodynamic evaluation in children with shock. J Pediatr. 1982;100:977–983

Razavi RS, Baker A, Qureshi SA, et al. Hemodynamic response to continuous infusion of dobutamine in Alagille’s syndrome; 2001.

Rozé JC, Tohier C, Maingueneau C, et al. Response to dobutamine and dopamine in the hypotensive very preterm infant. Arch Dis Child. 1993;69:59–63. DOI:10.1136/adc.69.1_Spec_No.59

Sakata Y, Iijima T, Yoshida I, et al. Effects of dopamine and dobutamine on systemic hemodynamics and myocardial metabolism in; 1991.

Trifonova NA, Ismail-Zade IA, Michelson VA. Value of dobutamine in children surgically treated for portal hypertension. Apropos of 23 cases. Cah; 1994.

Yan M, Webster LT, Blumer JL (2002) 3-O-methyldobutamine, a major metabolite of dobutamine in humans. Drug MetabDispos. 2002;30:519–524. DOI:10.1124/dmd.30.5.519